An array of mucocutaneous findings was identified in hospitalized children with multisystem inflammatory syndrome in children (MIS-C) or suspected MIS-C during the COVID-19 pandemic, reported a case series published in JAMA Dermatology.

Of the patients assessed, 83% developed mucocutaneous changes, with the most common being conjunctival injection, palmoplantar erythema, lip hyperemia, periorbital erythema and edema, strawberry tongue, and malar erythema. Other cutaneous morphologic findings included scarlatiniform eruptions, morbilliform eruptions, urticarial eruptions, and reticulated eruptions. Among those with mucocutaneous changes, 19 patients experienced fever a mean of 2.7 days (range, 1-7 days) prior to the recognition of the first mucocutaneous finding. The duration of mucocutaneous findings ranged from hours to days (median duration, 5 days [range, 0-11 days]).

Conjunctivitis, lip hyperemia or cracking, and palmoplantar erythema exhibited an even distribution across all ages; however, urticarial eruptions were noted in those below 2 years of age, and periorbital and palmoplantar edema were evident in those younger than 6 years.

Source: JAMA Dermatology